Our CSO, Anders Sandberg, comments on new assay data in BioStock interview
Date: 2024-04-23
Following our in-depth analysis of data from the initial phase Ib study, our analysis revealed that our vaccine candidate ALZ-101 has shown a positive effect on biomarkers closely associated with Alzheimer's disease. This development marks a crucial step forward in our mission to address this challenging disease!
In a recent interview with BioStock, our co-founder and CSO, Anders Sandberg, underscored the importance of these results. He highlighted how this achievement positions Alzinova AB for greater success as we move forward into the next phase of clinical trials.